Phenotypic and pharmacogenetic aspects of ovulation induction in WHO II anovulatory women

References

• Evans W E, Relling M V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487–491
   PubMed Web of Science ®Google Scholar
• Giacomini K M, Brett C M, Altman R B, Benowitz N L, Dolan M E, Flockhart D A, Johnson J A, Hayes D F, Klein T, Krauss R M, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 2007; 81: 328–345
   PubMed Web of Science ®Google Scholar
• Eberle M A, Ng P C, Kuhn K, Zhou L, Peiffer D A, Galver L, Viaud-Martinez K A, Lawley C T, Gunderson K L, Shen R, et al. Power to detect risk alleles using genome-wide tag SNP panels. PLoS Genetics 2007; 3: e170
   Google Scholar
• Broekmans F J, Knauff E AH, Valkenburg O, Laven J S, Eijkemans M J, Fauser B CJM. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG: Int J Obstet Gynaecol 2006; 113: 1210–1217
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–47
   PubMed Web of Science ®Google Scholar
• Durlinger A L, Gruijters M J, Kramer P, Karels B, Ingraham H A, Nachtigal M W, Uilenbroek J T, Grootegoed J A, Themmen A P. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 2002; 143: 1076–1084
   PubMed Web of Science ®Google Scholar
• Knight P G, Glister C. TGF-beta superfamily members and ovarian follicle development. Reproduction 2006; 132: 191–206
   PubMed Web of Science ®Google Scholar
• Gougeon A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocrinol Rev 1996; 17: 121–155
   PubMed Web of Science ®Google Scholar
• Casper R F, Mitwally M F. Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 2006; 91: 760–771
   PubMed Web of Science ®Google Scholar
• Insler V, Melmed H, Mashiah S, Monselise M, Lunenfeld B, Rabau E. Functional classification of patients selected for gonadotropic therapy. Obstet Gynecol 1968; 32: 620–626
   Google Scholar
• Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853–861
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrinol Rev 1997; 18: 774–800
   PubMed Web of Science ®Google Scholar
• Greenblatt R B, Barfield W E, Jungck E C, Ray A W. Induction of ovulation with MRL/41. Preliminary report. JAMA 1961; 178: 101–104
   PubMed Web of Science ®Google Scholar
• The Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in women. Fertil Steril 2006; 86: S187–S193
   Google Scholar
• Hugo S, Teresa S, Luigi D. Clomiphene citrate and ovulation induction. Reprod BioMed Online 2002; 4: 303–310
   Google Scholar
• Mikkelson T J, Kroboth P D, Cameron W J, Dittert L W, Chungi V, Manberg P J. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertil Steril 1986; 46: 392–396
   PubMed Web of Science ®Google Scholar
• Young S L, Opsahl M S, Fritz M A. Serum concentrations of enclomiphene and zuclomiphene across consecutive cycles of clomiphene citrate therapy in anovulatory infertile women. Fertil Steril 1999; 71: 639–644
   PubMed Web of Science ®Google Scholar
• Kerin J F, Liu J H, Phillipou G, Yen S S. Evidence for a hypothalamic site of action of clomiphene citrate in women. J Clin Endocrinol Metab 1985; 61: 265–268
   PubMed Web of Science ®Google Scholar
• Kettel L M, Roseff S J, Berga S L, Mortola J F, Yen S S. Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovary syndrome. Fertil Steril 1993; 59: 532–538
   PubMed Web of Science ®Google Scholar
• Dickey R P, Holtkamp D E. Development, pharmacology and clinical experience with clomiphene citrate. Hum Reprod Update 1996; 2: 483–506
   PubMed Web of Science ®Google Scholar
• Homburg R. The management of infertility associated with polycystic ovary syndrome. Reprod Biol Endocrinol 2003; 1: 109
   PubMedGoogle Scholar
• Lobo R A, Gysler M, March C M, Goebelsmann U, Mishell D R, Jr. Clinical and laboratory predictors of clomiphene response. Fertil Steril 1982; 37: 168–174
   PubMed Web of Science ®Google Scholar
• Polson D W, Kiddy D S, Mason H D, Franks S. Induction of ovulation with clomiphene citrate in women with polycystic ovary syndrome: the difference between responders and nonresponders. Fertil Steril 1989; 51: 30–34
   PubMed Web of Science ®Google Scholar
• Imani B, Eijkemans M J, te Velde E R, Habbema J D, Fauser B C. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 1998; 83: 2361–2365
   PubMed Web of Science ®Google Scholar
• Kurabayashi T, Suzuki M, Fujita K, Murakawa H, Hasegawa I, Tanaka K. Prognostic factors for ovulatory response with clomiphene citrate in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2006; 126: 201–205
   PubMed Web of Science ®Google Scholar
• Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004; 37: 277–285
   PubMed Web of Science ®Google Scholar
• Verit F F, Erel O, Kocyigit A. Association of increased total antioxidant capacity and anovulation in nonobese infertile patients with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril 2007; 88: 418–424
   Google Scholar
• Huirne J A, Lambalk C B, van Loenen A C, Schats R, Hompes P G, Fauser B C, Macklon N S. Contemporary pharmacological manipulation in assisted reproduction. Drugs 2004; 64: 297–322
   PubMed Web of Science ®Google Scholar
• Giudice E, Crisci C, Altarocca V, O'Brien M. Characterisation of a partially purified human menopausal gonadotropin preparation. J Clin Res 2001; 4: 27–34
   Google Scholar
• Weiss N. Gonadotrophin products: empowering patients to choose the product that meets their needs. Reprod Biomed Online 2007; 15: 31–37
   PubMed Web of Science ®Google Scholar
• Recombinant Human FSH Product Development Group. Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility. Hum Reprod Update 1998; 4: 862–881
   Google Scholar
• Tarlatzis B C, Fauser B CJM, Legro R S, Norman R J. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008; 89: 505–522
   PubMed Web of Science ®Google Scholar
• Lopez E, Gunby J, Daya S, Parrilla J J, Abad L, Balasch J. Ovulation induction in women with polycystic ovary syndrome: randomized trial of clomiphene citrate versus low-dose recombinant FSH as first line therapy. Reprod Biomed Online 2004; 9: 382–390
   PubMedGoogle Scholar
• Reitman M L, Schadt E E. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 2007; 117: 1226–1229
   PubMed Web of Science ®Google Scholar
• Barbieri R L. Clomiphene versus metformin for ovulation induction in polycystic ovary syndrome: The winner is …. J Clin Endocrinol Metab 2007; 92: 3399–3401
   Google Scholar
• Balen A H, Rutherford A J. Managing anovulatory infertility and polycystic ovary syndrome. BMJ 2007; 335: 663–666
   PubMed Web of Science ®Google Scholar
• Costello M F, Eden J A. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003; 79: 1–13
   PubMed Web of Science ®Google Scholar
• Legro R S, Barnhart H X, Schlaff W D, Carr B R, Diamond M P, Carson S A, Steinkampf M P, Coutifaris C, McGovern P G, Cataldo N A, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356: 551–566
   PubMed Web of Science ®Google Scholar
• Moll E, Bossuyt P MM, Korevaar J C, Lambalk C B, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 2006; 332: 1485
   PubMed Web of Science ®Google Scholar
• Shu Y, Brown C, Castro R A, Shi R J, Lin E T, Owen R P, Sheardown S A, Yue L, Burchard E G, Brett C M, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008; 83: 273–280
   PubMed Web of Science ®Google Scholar
• Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 1994; 372: 549–552
   PubMed Web of Science ®Google Scholar
• Legro R S, Barnhart H X, Schlaff W D, Carr B R, Diamond M P, Carson S A, Steinkampf M P, Coutifaris C, McGovern P G, Cataldo N A, et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab 2008; 93: 792–800
   PubMed Web of Science ®Google Scholar
• Biljan M M, Hemmings R, Brassard N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertil Steril 2005; 84: S95
   Web of Science ®Google Scholar
• Casper R F. Aromatase inhibitors in ovarian stimulation. J Steroid Biochem Mol Biol 2007; 106: 71–75
   PubMed Web of Science ®Google Scholar
• Tulandi T, Martin J, Al-Fadhli R, Kabli N, Forman R, Hitkari J, Librach C, Greenblatt E, Casper R F. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 2006; 85: 1761–1765
   PubMed Web of Science ®Google Scholar
• Dahlman-Wright K, Cavailles V, Fuqua S A, Jordan V C, Katzenellenbogen J A, Korach K S, Maggi A, Muramatsu M, Parker M G, Gustafsson J A. International union of pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 2006; 58: 773–781
   PubMed Web of Science ®Google Scholar
• Hill S M, Fuqua S A, Chamness G C, Greene G L, McGuire W L. Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res 1989; 49: 145–148
   PubMed Web of Science ®Google Scholar
• Sano M, Inoue S, Hosoi T, Ouchi Y, Emi M, Shiraki M, Orimo H. Association of estrogen receptor dinucleotide repeat polymorphism with osteoporosis. Biochem Biophys Res Commun 1995; 217: 378–383
   PubMed Web of Science ®Google Scholar
• Rexrode K M, Ridker P M, Hegener H H, Buring J E, Manson J E, Zee R YL. Polymorphisms and haplotypes of the estrogen receptor-β gene (ESR2) and cardiovascular disease in men and women. Clin Chem 2007; 53: 1749–1756
   PubMed Web of Science ®Google Scholar
• Sundarrajan C, Liao W, Roy A C, Ng S C. Association of oestrogen receptor gene polymorphisms with outcome of ovarian stimulation in patients undergoing IVF. Mol Hum Reprod 1999; 5: 797–802
   PubMed Web of Science ®Google Scholar
• Georgiou I, Konstantelli M, Syrrou M, Messinis I E, Lolis D E. Oestrogen receptor gene polymorphisms and ovarian stimulation for in vitro fertilization. Hum Reprod 1997; 12: 1430–1403
   PubMed Web of Science ®Google Scholar
• de Castro F, Moron F J, Montoro L, Galan J J, Hernandez D P, Padilla E S, Ramirez-Lorca R, Real L M, Ruiz A. Human controlled ovarian hyperstimulation outcome is a polygenic trait. Pharmacogenetics 2004; 14: 285–293
   PubMedGoogle Scholar
• Sundarrajan C, Liao W X, Roy A C, Ng S C. Association between estrogen receptor-beta gene polymorphisms and ovulatory dysfunctions in patients with menstrual disorders. J Clin Endocrinol Metab 2001; 86: 135–139
   PubMed Web of Science ®Google Scholar
• Yang-Feng T L, Seeburg P H, Francke U. Human luteinizing hormone-releasing hormone gene (LHRH) is located on short arm of chromosome 8 (region 8p11.2–p21). Somat Cell Mol Genet 1986; 12: 95–100
   PubMedGoogle Scholar
• Hrabovszky E, Kallo I, Szlavik N, Keller E, Merchenthaler I, Liposits Z. Gonadotropin-releasing hormone neurons express estrogen receptor-β. J Clin Endocrinol Metab 2007; 92: 2827–2830
   Google Scholar
• Bedecarrats G Y, Kaiser U B. Mutations in the human gonadotropin-releasing hormone receptor: insights into receptor biology and function. Semin Reprod Med 2007; 25: 368–378
   Google Scholar
• Themmen A PN, Huhtaniemi I T. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocrinol Rev 2000; 21: 551–583
   PubMed Web of Science ®Google Scholar
• Rousseau-Merck M F, Misrahi M, Atger M, Loosfelt H, Milgrom E, Berger R. Localization of the human luteinizing hormone/choriogonadotropin receptor gene (LHCGR) to chromosome 2p21. Cytogenet Cell Genet 1990; 54: 77–79
   PubMedGoogle Scholar
• Huhtaniemi I T, Themmen A P. Mutations in human gonadotropin and gonadotropin-receptor genes. Endocrine 2005; 26: 207–217
   Google Scholar
• Piersma D, Berns E MJJ, Verhoef-Post M, Uitterlinden A G, Braakman I, Pols H AP, Themmen A PN. A common polymorphism renders the luteinizing hormone receptor protein more active by improving signal peptide function and predicts adverse outcome in breast cancer patients. J Clin Endocrinol Metab 2006; 91: 1470–1476
   PubMed Web of Science ®Google Scholar
• Perez M M, Gromoll J, Behre H M, Gassner C, Nieschlag E, Simoni M. Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab 2000; 85: 3365–3369
   Google Scholar
• Laven J S, Mulders A G, Suryandari D A, Gromoll J, Nieschlag E, Fauser B C, Simoni M. Follicle-stimulating hormone receptor polymorphisms in women with normogonadotropic anovulatory infertility. Fertil Steril 2003; 80: 986–992
   PubMed Web of Science ®Google Scholar
• Aittomaki K, Lucena J L, Pakarinen P, Sistonen P, Tapanainen J, Gromoll J, Kaskikari R, Sankila E M, Lehvaslaiho H, Engel A R. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995; 82: 959–968
   PubMed Web of Science ®Google Scholar
• Gromoll J, Simoni M, Nieschlag E. An activating mutation of the follicle-stimulating hormone receptor autonomously sustains spermatogenesis in a hypophysectomized man. J Clin Endocrinol Metab 1996; 81: 1367–1370
   PubMed Web of Science ®Google Scholar
• Vasseur C, Rodien P, Beau I, Desroches A, Gerard C, de P L, Chaplot S, Savagner F, Croue A, Mathieu E, et al. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N Engl J Med 2003; 349: 753–759
   PubMed Web of Science ®Google Scholar
• Simoni M, Gromoll J, Nieschlag E. The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocrinol Rev 1997; 18: 739–773
   PubMed Web of Science ®Google Scholar
• Sudo S, Kudo M, Wada S, Sato O, Hsueh A J, Fujimoto S. Genetic and functional analyses of polymorphisms in the human FSH receptor gene. Mol Hum Reprod 2002; 8: 893–899
   PubMed Web of Science ®Google Scholar
• Loutradis D, Patsoula E, Minas V, Koussidis G A, Antsaklis A, Michalas S, Makrigiannakis A. FSH receptor gene polymorphisms have a role for different ovarian response to stimulation in patients entering IVF/ICSI-ET programs. J Assist Reprod Genet 2006; 23: 177–184
   PubMed Web of Science ®Google Scholar
• Jun J K, Yoon J S, Ku S Y, Choi Y M, Hwang K R, Park S Y, Lee G H, Lee W D, Kim S H, Kim J G, et al. Follicle-stimulating hormone receptor gene polymorphism and ovarian responses to controlled ovarian hyperstimulation for IVF-ET. J Hum Genet 2006; 51: 665–670
   PubMed Web of Science ®Google Scholar
• de Castro F, Ruiz R, Montoro L, Perez-Hernandez D, Sanchez-Casas P E, Real L M, Ruiz A. Role of follicle-stimulating hormone receptor Ser680Asn polymorphism in the efficacy of follicle-stimulating hormone. Fertil Steril 2003; 80: 571–576
   PubMed Web of Science ®Google Scholar
• de Castro F, Moron F J, Montoro L, Galan J J, Hernandez D P, Padilla E S, Ramirez-Lorca R, Real L M, Ruiz A. Human controlled ovarian hyperstimulation outcome is a polygenic trait. Pharmacogenetics 2004; 14: 285–293
   PubMedGoogle Scholar
• de Castro F, Moron F J, Montoro L, Real L M, Ruiz A. Pharmacogenetics of controlled ovarian hyperstimulation. Pharmacogenomics 2005; 6: 629–637
   PubMed Web of Science ®Google Scholar
• Klinkert E R, te Velde E R, Weima S, van Zandvoort P M, Hanssen R G, Nilsson P R, de Jong F H, Looman C W, Broekmans F J. FSH receptor genotype is associated with pregnancy but not with ovarian response in IVF. Reprod Biomed Online 2006; 13: 687–695
   PubMed Web of Science ®Google Scholar
• Wunsch A, Ahda Y, Banaz-Yasar F, Sonntag B, Nieschlag E, Simoni M, Gromoll J. Single-nucleotide polymorphisms in the promoter region influence the expression of the human follicle-stimulating hormone receptor. Fertil Steril 2005; 84: 446–453
   PubMedGoogle Scholar
• Yang C Q, Chan K Y, Ngan H Y, Khoo U S, Chiu P M, Chan Q K, Xue W C, Cheung A N. Single nucleotide polymorphisms of follicle-stimulating hormone receptor are associated with ovarian cancer susceptibility. Carcinogenesis 2006; 27: 1502–1506
   Google Scholar
• Hehenkamp W JK, Looman C WN, Themmen A PN, de Jong F H, te Velde E R, Broekmans F JM. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 2006; 91: 4057–4063
   PubMed Web of Science ®Google Scholar
• Kevenaar M E, Themmen A PN, Laven J SE, Sonntag B, Fong S L, Uitterlinden A G, de Jong F H, Pols H AP, Simoni M, Visser J A. Anti-Mullerian hormone and anti-Mullerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women. Hum Reprod 2007; 22: 1547–1554
   PubMed Web of Science ®Google Scholar
• Gemmell N J, Slate J. Heterozygote advantage for fecundity. PLoS One 2006; 1: e125
   Google Scholar
• Palmer J S, Zhao Z Z, Hoekstra C, Hayward N K, Webb P M, Whiteman D C, Martin N G, Boomsma D I, Duffy D L, Montgomery G W. Novel variants in growth differentiation factor 9 in mothers of dizygotic twins. J Clin Endocrinol Metab 2006; 91: 4713–4716
   PubMed Web of Science ®Google Scholar
• Kovanci E, Rohozinski J, Simpson J L, Heard M J, Bishop C E, Carson S A. Growth differentiating factor-9 mutations may be associated with premature ovarian failure. Fertil Steril 2007; 87: 143–146
   PubMed Web of Science ®Google Scholar
• Laven J SE, Fauser B CJM. Inhibins and adult ovarian function. Mol Cell Endocrinol 2004; 225: 37–44
   PubMed Web of Science ®Google Scholar
• Groome N P, Illingworth P J, O'Brien M, Pai R, Rodger F E, Mather J P, McNeilly A S. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996; 81: 1401–1405
   PubMed Web of Science ®Google Scholar
• Chand A L, Ooi G T, Harrison C A, Shelling A N, Robertson D M. Functional analysis of the human inhibin α subunit variant A257T and its potential role in premature ovarian failure. Hum Reprod 2007; 22: 3241–3248
   PubMed Web of Science ®Google Scholar
• Gough A C, Miles J S, Spurr N K, Moss J E, Gaedigk A, Eichelbaum M, Wolf C R. Identification of the primary gene defect at the cytochrome P450CYP2D locus. Nature 1990; 347: 773–776
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Dahl M L, Sjoqvist F, berg-Wistedt A, Humble M, Johansson I, Lundqvist E, Ingelman-Sundberg M. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341: 63
   PubMed Web of Science ®Google Scholar
• Johansson I, Lundqvist E, Bertilsson L, Dahl M, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci 1993; 90: 11825–11829
   PubMed Web of Science ®Google Scholar
• Jordan V C, O'Malley B W. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007; 20(25)5815–5824
   Google Scholar
• Beck J I, Boothroyd C, Proctor M, Farquhar C, Hughes E. Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation. Cochrane Database Syst Rev 2005; CD002249
   Google Scholar
• Boostanfar R, Jain J K, Mishell D R, Paulson R J. A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertil Steril 2001; 75: 1024–1026
   PubMed Web of Science ®Google Scholar
• Overbeek A, Kuijper EAM, Hendriks ML, Ketel IJG, Hompes PGA, Homburg R, Lambalk CB. More clomiphene citrate resistance in relation to follicle stimulating-hormone receptor 680-polymorphism in polycystic ovary syndrome. Human Reproduction 2008; 23(Supplement 1)i186
   Google Scholar